221 interactions on record
MAOI antidepressants slow amphetamine metabolism, increasing norepinephrine release and risk of hypertensive crisis, toxic neurological effects, and potentially fatal malignant hyperpyrexia.
Source: NLP:amphetamine extended-release
MAOIs slow amphetamine metabolism, potentiating effects and risk of hypertensive crisis, neurological toxicity, and potentially fatal malignant hyperpyrexia.
Source: NLP:amphetamine sulfate
Apraclonidine should not be used in patients receiving MAO inhibitors.
Source: NLP:apraclonidine
Contraindicated due to increased risk of serotonin syndrome and/or elevated blood pressure. Use within 14 days before or after MAOI treatment is contraindicated.
Source: NLP:buspirone hydrochloride
Contraindicated in patients receiving MAO inhibitors (Type A or B).
Source: NLP:carbidopa and levodopa
Increased adrenergic tone risk. Use is contraindicated in patients receiving nonselective MAO inhibitors.
Source: NLP:carbidopa, levodopa and entacapone
Clomipramine should not be used with MAO inhibitors.
Source: NLP:clomipramine hydrochloride
Clomipramine should not be used with MAO inhibitors.
Source: NLP:clomipramine hydrochloride capsules
Life-threatening interaction with MAO inhibitors; contraindicated use.
Source: NLP:cyclobenzaprine
Life-threatening interactions with MAO inhibitors; serotonin syndrome reported.
Source: NLP:cyclobenzaprine hydrochloride
Dexmethylphenidate hydrochloride extended-release should not be used in patients being treated with MAO Inhibitors currently or within the preceding 2 weeks.
Source: NLP:dexmethylphenidate hydrochloride
Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure. Do not use concomitantly or within 14 days after discontinuing MAOI.
Source: NLP:dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
Slow amphetamine metabolism, potentiating effects and increasing norepinephrine release. Can cause hypertensive crisis, neurological toxicity, malignant hyperpyrexia, and potentially fatal results.
Source: NLP:dextroamphetamine sulfate
Contraindicated with CYP3A4 inhibitors including macrolide antibiotics and protease inhibitors.
Source: NLP:dihydroergotamine mesylate
Diphenoxylate may interact with MAOIs and precipitate hypertensive crisis. Avoid use and monitor for hypertensive crisis signs.
Source: NLP:diphenoxylate hydrochloride and atropine sulfate
Potential additive effect on known systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.
Source: NLP:dorzolamide hydrochloride and timolol maleate
Doxepin should not be administered in patients on MAOIs within the past two weeks.
Source: NLP:doxepin
Serious side effects and death reported with concomitant use. MAO inhibitors must be discontinued at least 2 weeks prior to initiating doxepin therapy.
Source: NLP:doxepin hydrochloride
Concomitant use should be avoided due to potential for increased blood pressure.
Source: NLP:droxidopa
OATP1B1 inhibitors that significantly increase elagolix plasma concentrations are contraindicated due to increased risk of elagolix-associated adverse reactions.
Source: NLP:elagolix and estradiol and norethisterone
Potent CYP3A4 inhibitors significantly increase eletriptan hydrobromide exposure. Should not be used within at least 72 hours of treatment with potent CYP3A4 inhibitors.
Source: NLP:eletriptan hydrobromide
Concomitant use may increase risk of angioedema. Avoid concomitant use.
Source: NLP:everolimus
Concomitant use of CYP1A2 inhibitors increases plasma Cmax and AUC of VEOZAH. VEOZAH is contraindicated in individuals using CYP1A2 inhibitors.
Source: NLP:fezolinetant
Concomitant use of isosorbide dinitrate with phosphodiesterase inhibitors in any form is contraindicated.
Source: NLP:isosorbide dinitrate
Concomitant use of isosorbide mononitrate with phosphodiesterase inhibitors in any form is contraindicated.
Source: NLP:isosorbide mononitrate
MAOI antidepressants slow amphetamine metabolism, increasing monoamine release causing hypertensive crisis, toxic neurological effects, and potentially fatal malignant hyperpyrexia.
Source: NLP:lisdexamfetamine
MAOI antidepressants slow amphetamine metabolism, increasing effects on norepinephrine release. Can cause hypertensive crisis, toxic neurological effects, and malignant hyperpyrexia with potentially fatal results.
Source: NLP:lisdexamfetamine dimesylate oral
Concomitant use increases mavacamten exposure, which may increase the risk of heart failure due to systolic dysfunction. Contraindicated.
Source: NLP:mavacamten
Do not use methylphenidate hydrochloride within 2 weeks of MAO inhibitor use due to contraindication.
Source: NLP:methylphenidate hydrochloride
Increased risk of hypertension; concomitant use should be avoided.
Source: NLP:metoclopramide
Increased risk of hypertension; avoid concomitant use.
Source: NLP:metoclopramide hydrochloride
Avoid use with midodrine.
Source: NLP:midodrine hydrochloride
Co-administration increases mitapivat plasma concentrations, increasing risk of adverse reactions. Avoid concomitant use.
Source: NLP:mitapivat
Concomitant use of nitroglycerin with phosphodiesterase inhibitors in any form is contraindicated.
Source: NLP:nitroglycerin
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Contraindicated due to increased risk of nonselective MAO inhibition that may lead to hypertensive crisis.
Source: NLP:rasagiline
Contraindicated due to increased risk of nonselective MAO inhibition that may lead to hypertensive crisis.
Source: NLP:rasagiline mesylate
Rizatriptan benzoate is contraindicated in patients taking MAO-A inhibitors. MAO-A inhibitors increase systemic exposure of rizatriptan and its metabolite.
Source: NLP:rizatriptan benzoate
Concomitant use is contraindicated due to increased risk of angioedema.
Source: NLP:sacubitril and valsartan
MAO-A inhibitors increase systemic exposure of sumatriptan 7-fold. Use of sumatriptan in patients receiving MAO-A inhibitors is contraindicated.
Source: NLP:sumatriptan
MAO-A inhibitors increase sumatriptan systemic exposure by 7-fold, contraindicated for concurrent use.
Source: NLP:sumatriptan succinate
MAO-A inhibitors increase systemic exposure of orally administered sumatriptan 7-fold. Use is contraindicated.
Source: NLP:sumatriptan and naproxen sodium
MAO-A inhibitors increase systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Concomitant use is contraindicated.
Source: NLP:zolmitriptan
Both classes are vasodilators; concomitant use can potentially cause symptomatic hypotension. Caution is advised.
Source: NLP:alfuzosin hydrochloride
Carbonic anhydrase inhibitors may increase risk of lactic acidosis by decreasing serum bicarbonate and inducing metabolic acidosis.
Source: NLP:alogliptin and metformin hydrochloride
Increased risk of angioedema when used with benazepril.
Source: NLP:amlodipine besylate and benazepril hydrochloride
In elderly, volume-depleted, or renally impaired patients, coadministration may result in deterioration of renal function including possible acute renal failure. May attenuate antihypertensive effect. Monitor renal function.
Source: NLP:amlodipine and valsartan
Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.
Source: NLP:amlodipine and olmesartan medoxomil
May potentiate cardiovascular effects of arformoterol. Use with extreme caution.
Source: NLP:arformoterol tartrate
Increases asciminib Cmax and AUC, which may increase risk of adverse reactions. Closely monitor during concomitant use at 200 mg twice daily.
Source: NLP:asciminib
Concomitant use increases defactinib exposure, which may increase the risk of adverse reactions. Avoid concomitant use.
Source: NLP:avutometinib potassium and defactinib hydrochloride
COX-2 inhibitors increase risk of renal dysfunction and acute renal failure when combined with azilsartan. Effects usually reversible. May attenuate antihypertensive effect.
Source: NLP:azilsartan kamedoxomil and chlorthalidone
Increased risk of angioedema with concomitant use.
Source: NLP:benazepril hydrochloride
Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema.
Source: NLP:benazepril hydrochloride and hydrochlorothiazide
Potential additive effect on known systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.
Source: NLP:brinzolamide
Dual blockade of the RAS is associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Monitor blood pressure, renal function, and electrolytes.
Source: NLP:candesartan
May result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensive effect. Risk increased in elderly, volume-depleted, or renal-compromised patients.
Source: NLP:candesartan cilexetil
Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.
Source: NLP:captopril
May increase risk of hypotension and severe bradycardia due to catecholamine depletion.
Source: NLP:carvedilol
May diminish antihypertensive effect; in elderly, volume depleted, or renally impaired patients may result in deterioration of renal function.
Source: NLP:celecoxib
Increases risk of QT prolongation and ventricular arrhythmias. Maximum citalopram dosage is 20 mg daily when used concomitantly.
Source: NLP:citalopram hydrobromide
Increased hematotoxicity and immunosuppression may result from combined effect; ACE inhibitors can cause leukopenia.
Source: NLP:cyclophosphamide
MAO inhibitors prolong and intensify the anticholinergic effects of cyproheptadine.
Source: NLP:cyproheptadine hydrochloride
Coadministration may increase dasatinib concentrations and risk of toxicity. Avoid concomitant use or consider dasatinib dose reduction.
Source: NLP:dasatinib
May result in deterioration of renal function including possible acute renal failure in elderly, volume-depleted, or renally impaired patients. NSAIDs may diminish antihypertensive effect.
Source: NLP:diclofenac sodium
Risk of severe hypertension. Reduce recommended dopamine HCl injection dosage.
Source: NLP:dopamine hydrochloride
Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.
Source: NLP:dorzolamide hydrochloride
Concomitant administration can result in additive blood pressure lowering effects and symptomatic hypotension.
Source: NLP:doxazosin
Increased risk for angioedema in patients taking concomitant neprilysin inhibitors with enalapril maleate.
Source: NLP:enalapril maleate
Concomitant neprilysin inhibitors may increase risk for angioedema in patients taking enalapril.
Source: NLP:enalapril maleate and hydrochlorothiazide
Potentiate the effects of epinephrine, may cause serious hypertension.
Source: NLP:epinephrine
Erythromycin increases concentrations of HMG-CoA reductase inhibitors.
Source: NLP:erythromycin ethylsuccinate
May potentiate cardiovascular effects of formoterol. Use with extreme caution.
Source: NLP:formoterol fumarate
May potentiate cardiovascular effects of formoterol. Use with extreme caution.
Source: NLP:formoterol fumarate dihydrate
Synergistic effect expected when given concurrently with galantamine.
Source: NLP:galantamine
Synergistic effect expected when given concurrently with galantamine and other cholinesterase inhibitors.
Source: NLP:galantamine hydrobromide
Initial small test dose advisable; concomitant use may cause excessive narcotic effects or MAOI interaction.
Source: NLP:hydromorphone hydrochloride
Concomitant use increases imlunestrant exposure, which may increase the risk of adverse reactions. Avoid concomitant use; if unavoidable, reduce imlunestrant dosage.
Source: NLP:imlunestrant
Coadministration may result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.
Source: NLP:irbesartan
COX-2 inhibitors can reduce diuretic and antihypertensive effects, and may result in deterioration of renal function including acute renal failure. Monitor renal function and blood pressure.
Source: NLP:irbesartan and hydrochlorothiazide
MAO inhibitors combined with isoflurane may increase risk of hemodynamic instability during surgery or medical procedures.
Source: NLP:isoflurane
Strong CYP3A4 inhibitors increase ribociclib exposure and may increase incidence and severity of adverse reactions including QTcF prolongation. Dose reduction required if coadministration cannot be avoided.
Source: NLP:letrozole and ribociclib
Coadministration may result in deterioration of renal function including possible acute renal failure; may attenuate antihypertensive effect.
Source: NLP:lisinopril
COX-2 inhibitors may result in deterioration of renal function, including possible acute renal failure, in elderly patients, volume-depleted patients, or those with compromised renal function.
Source: NLP:lisinopril and hydrochlorothiazide
Additive depression of the central nervous system when administered with lorazepam injection.
Source: NLP:lorazepam
Avoid concomitant use with strong CYP3A inhibitors; reduce lorlatinib dose if unavoidable. Increases lorlatinib plasma concentrations, increasing adverse reactions.
Source: NLP:lorlatinib
Dual blockade of RAS associated with increased risks of hypotension, syncope, hyperkalemia, and acute renal failure. Avoid combined use; if necessary, closely monitor blood pressure, renal function, and electrolytes.
Source: NLP:losartan potassium
Risk of deterioration of renal function including possible acute renal failure, and reduced diuretic and antihypertensive effects. Monitor renal function periodically.
Source: NLP:losartan potassium and hydrochlorothiazide
Concomitant use increases mavorixafor Cmax and AUC, increasing risk of adverse reactions. Requires dosage reduction to 200 mg daily.
Source: NLP:mavorixafor
May increase risk of lactic acidosis with metformin. Consider more frequent monitoring.
Source: NLP:metformin
May increase methotrexate plasma concentrations, increasing risk of severe adverse reactions and potentially reducing clinical effectiveness.
Source: NLP:methotrexate
Additive catecholamine-depleting effect with risk of hypotension and bradycardia. Possibly significant hypertension may occur up to 14 days after discontinuation.
Source: NLP:metoprolol tartrate
May potentiate effect on the cardiovascular system. Use with extreme caution.
Source: NLP:mometasone furoate and formoterol fumarate dihydrate
Concomitant use may increase risk of skeletal muscle effects. See WARNINGS section for additional details.
Source: NLP:niacin
Concomitant use increases nilotinib concentrations, which may increase the risk of nilotinib toxicities. Avoid concomitant use or reduce nilotinib dose if coadministration cannot be avoided.
Source: NLP:nilotinib
Gastric acid reducing agent. Decreases nirogacestat exposure, which may reduce effectiveness of nirogacestat.
Source: NLP:nirogacestat
Co-administration may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. Antihypertensive effect may be attenuated.
Source: NLP:olmesartan medoxomil
COX-2 inhibitors may result in deterioration of renal function including acute renal failure in elderly, volume-depleted, or renal-compromised patients. May attenuate antihypertensive effect.
Source: NLP:olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide
Dual blockade of the renin-angiotensin system is associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.
Source: NLP:olmesartan medoxomil and hydrochlorothiazide
Dual blockade of the RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure. Avoid combined use.
Source: NLP:olmesartan medoxomil-hydrochlorothiazide
Co-administration increases palovarotene exposure, which may increase risk of adverse reactions. Avoid concomitant use.
Source: NLP:palovarotene
Antagonistic effects with decreased phenylephrine blood pressure effect.
Source: NLP:phenylephrine hydrochloride
Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other hyperkalemia risk factors.
Source: NLP:potassium chloride
RAAS inhibitors that produce potassium retention; monitor for hyperkalemia with concomitant use.
Source: NLP:potassium chloride for oral solution
Produce potassium retention by inhibiting aldosterone production; closely monitor potassium levels.
Source: NLP:potassium citrate
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphates
Patients taking concomitant neprilysin inhibitor therapy may be at increased risk for angioedema.
Source: NLP:ramipril
Concomitant use increases remibrutinib exposure and risk of adverse reactions. Avoid concomitant use.
Source: NLP:remibrutinib
Concomitant use may increase repotrectinib exposure and increase incidence and severity of adverse reactions. Avoid concomitant use.
Source: NLP:repotrectinib
Strong inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations and increase risk of adverse reactions. Concomitant use should be avoided.
Source: NLP:ruxolitinib
Concomitant use of MAO inhibitors and sevoflurane may increase the risk of hemodynamic instability during surgery or medical procedures.
Source: NLP:sevoflurane
Concomitant use of sildenafil citrate with strong CYP3A inhibitors is not recommended.
Source: NLP:sildenafil
Concomitant use of sildenafil citrate with strong CYP3A inhibitors is not recommended.
Source: NLP:sildenafil citrate
Avoid concomitant use due to increased risk of severe and potentially fatal hyperkalemia. If unavoidable, closely monitor serum potassium concentrations.
Source: NLP:dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride
ACE inhibitors can increase serum potassium; concomitant use with spironolactone may lead to severe hyperkalemia. Check potassium levels when therapy is altered.
Source: NLP:spironolactone
Concomitant administration may lead to severe hyperkalemia.
Source: NLP:spironolactone and hydrochlorothiazide
Concomitant use can potentially cause symptomatic hypotension.
Source: NLP:tamsulosin hydrochloride
COX-2 inhibitors may result in deterioration of renal function and reduce the diuretic, natriuretic, and antihypertensive effects similar to NSAIDs.
Source: NLP:telmisartan and hydrochlorothiazide
Concomitant use increases the risk of bleeding.
Source: NLP:tirofiban
Substantial increase in tolvaptan exposure expected. Avoid co-administration.
Source: NLP:tolvaptan
Increase tramadol plasma concentration, potentially causing seizures, serotonin syndrome, opioid toxicity, and potentially fatal respiratory depression.
Source: NLP:tramadol hydrochloride and acetaminophen
Concomitant use may increase tramadol plasma concentration and increase M1 levels, resulting in seizures, serotonin syndrome, and potentially fatal respiratory depression.
Source: NLP:tramadol/apap
Increase tretinoin plasma concentrations, which may increase risk of adverse reactions. Avoid if possible; monitor frequently if unavoidable.
Source: NLP:tretinoin
Increased risk of hyperkalemia when potassium-sparing agents like triamterene are used with ACE inhibitors.
Source: NLP:triamterene
Greatly increased risk of hyperkalemia when potassium-sparing agents used with ACE inhibitors. Serum potassium should be monitored frequently.
Source: NLP:triamterene and hydrochlorothiazide
Dual RAS blockade associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use; closely monitor if necessary.
Source: NLP:valsartan
Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.
Source: NLP:valsartan and hydrochlorothiazide
Avoid concomitant use. Decreases ziftomenib exposure and may reduce efficacy of KOMZIFTI.
Source: NLP:ziftomenib
Concomitant use with other carbonic anhydrase inhibitors is not advisable due to possible additive effects.
Source: NLP:acetazolamide
Concomitant use with other carbonic anhydrase inhibitors is not advisable due to possible additive effects.
Source: NLP:acetazolamide extended-release
Co-administration results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for hypotension and edema.
Source: NLP:amlodipine and atorvastatin
Strong CYP2C8 inhibitors increase steady-state exposure of apalutamide active moieties. Dose reduction of apalutamide is recommended.
Source: NLP:apalutamide
Caution should be used when concomitantly administering MAO inhibitors and armodafinil.
Source: NLP:armodafinil
Aspirin may diminish the hyponatremic and hypotensive effects of ACE inhibitors through indirect effects on the renin-angiotensin pathway.
Source: NLP:aspirin and dipyridamole
Aspirin may diminish the hyponatremic and hypotensive effects of ACE inhibitors through indirect effects on the renin-angiotensin pathway.
Source: NLP:aspirin and extended-release dipyridamole
Prolonged or accelerated half-life of metronidazole or concomitant medications; use with caution.
Source: NLP:bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride
Coadministration increases bortezomib exposure, which may increase risk of bortezomib toxicities. Monitor for toxicity signs and consider dose reduction.
Source: NLP:bortezomib
Can increase plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects; discontinuation may result in decreased efficacy or withdrawal.
Source: NLP:buprenorphine
CYP3A inhibitors may increase rilpivirine plasma concentrations.
Source: NLP:cabotegravir and rilpivirine
Coadministration with strong CYP3A inhibitors increased capmatinib exposure, which may increase the incidence and severity of adverse reactions. Closely monitor patients for adverse reactions.
Source: NLP:capmatinib
Reduce gastric acidity and should be avoided as they may lower bioavailability of cefuroxime axetil.
Source: NLP:cefuroxime axetil
Drugs which inhibit CYP2D6 also inhibit the metabolism of cevimeline, requiring caution in use.
Source: NLP:cevimeline hydrochloride
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of clemastine fumarate.
Source: NLP:clemastine fumarate
Strong CYP3A4 inhibitors may increase plasma concentrations of clindamycin; monitor for adverse reactions.
Source: NLP:clindamycin palmitate hydrochloride (pediatric)
Concomitant administration may increase risk of cocaine toxicity due to reduced plasma cholinesterase activity affecting cocaine metabolism.
Source: NLP:cocaine hydrochloride nasal
Cyclopentolate may interfere with the ocular anti-hypertensive action of ophthalmic cholinesterase inhibitors.
Source: NLP:cyclopentolate hydrochloride
Concomitant use with PPIs decreases dacomitinib concentrations, which may reduce VIZIMPRO efficacy. Avoid concomitant use; use locally-acting antacids or H2-receptor antagonist instead.
Source: NLP:dacomitinib
May increase risk of myopathy with elevated CPK levels when used concomitantly. Consider temporarily suspending HMG-CoA reductase inhibitors in patients receiving daptomycin.
Source: NLP:daptomycin
May potentiate or be potentiated by diazepam action. Careful consideration should be given when combining.
Source: NLP:diazepam
Concomitant use requires adequate hydration and renal function assessment at beginning of treatment.
Source: NLP:diclofenac
When administered concomitantly, patients should be adequately hydrated and renal function assessed at baseline.
Source: NLP:diclofenac sodium, methyl salicylate
NSAIDs may diminish antihypertensive effect; in elderly, volume-depleted, or renally impaired patients, may cause renal function deterioration including acute renal failure.
Source: NLP:diclofenac sodium and misoprostol
NSAIDs may diminish antihypertensive effect and can cause renal impairment in elderly, volume-depleted, or renally impaired patients.
Source: NLP:diclofenac sodium, kinesiology tape
May increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride.
Source: NLP:dicyclomine hydrochloride
May impair digoxin excretion by declining GFR or tubular secretion. Monitor renal function and digoxin levels.
Source: NLP:digoxin
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of diphenhydramine hydrochloride.
Source: NLP:diphenhydramine hydrochloride
Dipyridamole may counteract anticholinesterase effect of cholinesterase inhibitors, potentially aggravating myasthenia gravis.
Source: NLP:dipyridamole
Concomitant administration can result in additive blood pressure lowering effects and symptomatic hypotension. Monitor blood pressure and symptoms of hypotension.
Source: NLP:doxazosin mesylate
May cause significant increases or decreases in plasma concentrations of estrogen and progestin.
Source: NLP:drospirenone and ethinyl estradiol
Significant changes (increase or decrease) in plasma concentrations of estrogen and progestin have been noted in some cases.
Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium
May cause significant changes (increase or decrease) in plasma concentrations of estrogen and progestin.
Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Coadministration increases entrectinib plasma concentrations, which could increase frequency or severity of adverse reactions. Dose reduction required for patients ≥2 years; avoid in patients <2 years.
Source: NLP:entrectinib
Potentiate the effects of epinephrine.
Source: NLP:epinephrine in sodium chloride
Risk of hyperkalemia increases when combined with eplerenone; close monitoring of serum potassium and renal function recommended.
Source: NLP:eplerenone
Peripheral COMT inhibitors may interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.
Source: NLP:fluorodopa f18
Elevate gastric pH and reduce gefitinib plasma concentrations. Avoid concomitant use if possible; if required, separate dosing by 12 hours.
Source: NLP:gefitinib
May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.
Source: NLP:glimepiride
May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.
Source: NLP:glipizide
MAO inhibitors should be used with caution in patients receiving hydralazine.
Source: NLP:hydralazine hydrochloride
Icatibant may attenuate the antihypertensive effect of ACE inhibitors through pharmacodynamic interaction as a bradykinin B2 receptor antagonist.
Source: NLP:icatibant
FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors due to bradykinin B2 receptor antagonism.
Source: NLP:icatibant acetate
Imatinib increases plasma concentration of certain HMG-CoA reductase inhibitors; use caution with drugs having narrow therapeutic window.
Source: NLP:imatinib
Imatinib increases plasma concentration of certain CYP3A4 metabolized HMG-CoA reductase inhibitors. Use caution with drugs that have narrow therapeutic window.
Source: NLP:imatinib mesylate
May diminish antihypertensive effect and result in deterioration of renal function, including acute renal failure, in elderly, volume-depleted, or renal-impaired patients.
Source: NLP:indomethacin
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart-szjj
May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin degludec
May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin glargine
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin glulisine
May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin human
May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
Source: NLP:insulin lispro-aabc
Reduce gastric acidity and impair ketoconazole absorption from tablets. Ketoconazole should be taken with acidic beverage during coadministration.
Source: NLP:ketoconazole
Strong CYP3A4 inhibitors may significantly increase lacosamide exposure in patients with renal or hepatic impairment. Dose reduction may be necessary.
Source: NLP:lacosamide
Patients with renal or hepatic impairment taking strong CYP3A4 inhibitors may have significant increase in lacosamide exposure. Dose reduction may be necessary.
Source: NLP:lacosamide oral solution
Lanthanum carbonate may reduce bioavailability of ACE inhibitors. Do not administer within 2 hours of lanthanum carbonate dosing.
Source: NLP:lanthanum carbonate
Increased risk of serotonin syndrome when combined with lasmiditan; use with caution.
Source: NLP:lasmiditan
Significant changes in plasma levels of estrogen and progestin have been noted with co-administration.
Source: NLP:levonorgestrel / ethinyl estradiol and ethinyl estradiol
May cause hypochlorhydria and affect intragastric pH, reducing levothyroxine absorption. Monitor patients appropriately.
Source: NLP:levothyroxine sodium
May decrease serum lithium concentrations by increased urinary excretion. Monitor serum lithium concentration more frequently during initiation and dosage changes.
Source: NLP:lithium carbonate
Potential for drug-drug interactions as meclizine is metabolized by CYP2D6; monitor for adverse reactions and clinical effect.
Source: NLP:meclizine
Potential for drug-drug interaction as meclizine is metabolized by CYP2D6; monitor for adverse reactions and clinical effect.
Source: NLP:meclizine hydrochloride
Significant changes (increase or decrease) in plasma progestin levels may occur with co-administration.
Source: NLP:medroxyprogesterone acetate
Concomitant use with meloxicam may diminish antihypertensive effect. In elderly, volume-depleted, or renally impaired patients, may result in deterioration of renal function. Monitor blood pressure and renal function.
Source: NLP:meloxicam
Carbonic anhydrase inhibitors alter urine pH towards alkaline conditions, reducing memantine clearance by about 80% and potentially leading to drug accumulation and increased adverse effects.
Source: NLP:memantine
Carbonic anhydrase inhibitors alter urine pH towards alkaline conditions, which may reduce memantine clearance by about 80% and lead to drug accumulation and increased adverse effects.
Source: NLP:memantine hydrochloride oral
Carbonic anhydrase inhibitors may alter urine pH towards alkaline conditions, reducing memantine clearance by about 80% and leading to drug accumulation.
Source: NLP:memantine hydrochloride and donepezil hydrochloride
May increase risk of lactic acidosis with metformin. Consider more frequent monitoring.
Source: NLP:metformin hydrochloride
Concomitant use may increase unconjugated DM4 exposure, increasing the risk of ELAHERE adverse reactions. Closely monitor patients for adverse reactions.
Source: NLP:mirvetuximab soravtansine
Caution should be used when concomitantly administering MAO inhibitors and modafinil.
Source: NLP:modafinil
NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
Source: NLP:naproxen
May cause significant increases or decreases in plasma levels of estrogen and progestin, potentially decreasing contraceptive effectiveness.
Source: NLP:norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate
Inhibitors may increase phenobarbital exposure, increasing risk of adverse reactions. Closely monitor and consider dosage adjustment.
Source: NLP:phenobarbital sodium
Simultaneous administration may potentiate effects; caution should be exercised due to additive cholinesterase inhibition.
Source: NLP:physostigmine salicylate
May produce unfavorable interactions with potassium supplements, risk of hyperkalemia.
Source: NLP:potassium bicarbonate
Concomitant administration results in additive blood pressure lowering effects and symptomatic hypotension.
Source: NLP:prazosin hydrochloride
Concomitant use may increase incidence of extrapyramidal effects; use with caution.
Source: NLP:promethazine hydrochloride
ACE inhibitors combined with beta-blockers can cause hypotension, particularly during acute myocardial infarction.
Source: NLP:propranolol hydrochloride
Carbonic-anhydrase inhibitors alkalinize urine and reduce renal elimination of quinidine.
Source: NLP:quinidine gluconate
Alkalinize urine and reduce renal elimination of quinidine, increasing quinidine levels.
Source: NLP:quinidine sulfate tablet
Concomitant use increases quizartinib systemic exposure, which may increase risk of adverse reactions. VANFLYTA dosage reduction recommended.
Source: NLP:quizartinib
Proton pump inhibitors decrease rilzabrutinib exposure due to pH-dependent solubility, potentially reducing efficacy. Avoid concomitant use.
Source: NLP:rilzabrutinib
Coadministration increases ripretinib and active metabolite (DP-5439) exposure, which may increase the risk of adverse reactions. Monitor patients more frequently.
Source: NLP:ripretinib
Co-administration may increase sunitinib plasma concentrations. Consider dose reduction of sunitinib malate.
Source: NLP:sunitinib malate
BCRP inhibitors may increase talazoparib exposure; monitor for increased adverse reactions and modify dosage as recommended.
Source: NLP:talazoparib
COX-2 inhibitors may deteriorate renal function and cause acute renal failure in elderly, volume-depleted, or renally compromised patients. May attenuate antihypertensive effect. Monitor renal function periodically.
Source: NLP:telmisartan
Potential additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration is not recommended.
Source: NLP:ddorzolamide hydrochloride timolol maleate
Concomitant use may increase unconjugated MMAE exposure, increasing risk of TIVDAK adverse reactions. Close monitoring for adverse reactions recommended.
Source: NLP:tisotumab vedotin
Monitor patient for appearance or worsening of metabolic acidosis when co-administered with other carbonic anhydrase inhibitors.
Source: NLP:topiramate
Tropicamide may interfere with the antihypertensive action of ophthalmic cholinesterase inhibitors.
Source: NLP:tropicamide
Concomitant use increases venlafaxine and ODV levels, which may increase toxicity risk. Consider reducing venlafaxine dose.
Source: NLP:venlafaxine
Increases Cmax and AUC of venlafaxine and O-desmethylvenlafaxine, potentially increasing toxicity risk. Consider dose reduction.
Source: NLP:venlafaxine hydrochloride